ClinicalTrials.gov record
Recruiting Phase 3 Interventional

A Study of Navenibart in Participants With Hereditary Angioedema

ClinicalTrials.gov ID: NCT06842823

Public ClinicalTrials.gov record NCT06842823. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 5, 2026, 1:38 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Navenibart in Participants With Hereditary Angioedema (HAE)

Study identification

NCT ID
NCT06842823
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 3
Lead sponsor
Astria Therapeutics, Inc.
Industry
Enrollment
145 participants

Conditions and interventions

Interventions

  • Placebo Drug
  • navenibart Drug

Drug

Eligibility (public fields only)

Age range
12 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 19, 2025
Primary completion
Feb 28, 2027
Completion
Aug 31, 2027
Last update posted
May 3, 2026

2025 – 2027

United States locations

U.S. sites
20
U.S. states
14
U.S. cities
19
Facility City State ZIP Site status
Site 9 Birmingham Alabama 35209 Recruiting
Site 2 Scottsdale Arizona 85251 Recruiting
Site 3 Little Rock Arkansas 72205 Recruiting
Site 26 San Diego California 92122 Recruiting
Site 14 San Diego California 92123, Recruiting
Site 4 Santa Monica California 90404 Recruiting
Site 1 Walnut Creek California 94598 Recruiting
Site 8 Centennial Colorado 80112 Recruiting
Site 11 Colorado Springs Colorado 80907 Recruiting
Site 25 Tampa Florida 33613 Recruiting
Site 69 Weston Florida 33331 Recruiting
Site 43 Overland Park Kansas 66211-1318 Withdrawn
Site 6 Wheaton Maryland 20902 Recruiting
Site 67 Boston Massachusetts 02114 Recruiting
Site 13 Detroit Michigan 48202 Recruiting
Site 10 St Louis Missouri 63141 Recruiting
Site 7 Cincinnati Ohio 45236 Recruiting
Site 12 Toledo Ohio 43617 Recruiting
Site 15 Hummelstown Pennsylvania 17036 Recruiting
Site 86 Dallas Texas 75231 Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 67 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06842823, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 3, 2026 · Synced May 5, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06842823 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →